Bristol-myers Squibb Compnay

Other

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Université Louis Pasteur

Peter R Reczek

John E Starrett, Jr

Jacek Ostrowski

Pierre H Chambon

Muzammil M Mansuri

David R Tortolani

Fred Christopher Zusi

Kuo-Long Yu

Hinrich Gronemeyer

Anna M Ericsson

Alain Martel

Anne Marinier

Kenneth M Tramposch

Xina Nair

Violetta Iotzova

Methods and compositions for treating various disorders by administering a therapeutically effective amount of a retinoic acid receptor antagonist alone or in combination or in conjunction with other therapeutic agents to promote angiogenesis are provided. Also provided are methods for obtaining additional retinoic acid receptor antagonists for use as therapeutic agents to promote angiogenesis.

Retinoic acid receptor antagonists as promoters of angiogenesis

The present invention provides compositions and methods for treating an animal, preferably a human, suffering from or predisposed to a physical disorder by administering an effective amount of a composition comprising at least one RAR antagonist, preferably an RAR&agr; antagonist, and at least one RXR agonist. The combination of an RXR agonist, which has no therapeutic effects alone, with an RAR antagonist allows the use of lower doses of the RAR antagonist than were previously thought to be efficacious; this approach obviates many of the undesirable physiological side-effects of treatment with RAR antagonists.

Therapeutic combinations of RAR antagonists and RXR agonists and use thereof

The present invention provides compositions and methods for treating an animal, preferably a human, suffering from or predisposed to a physical disorder by administering an effective amount of a composition comprising at least one RAR antagonist, preferably an RAR.alpha. antagonist, and at least one RXR agonist. The combination of an RXR agonist, which has no therapeutic effects alone, with an RAR antagonist allows the use of lower doses of the RAR antagonist than were previously thought to be efficacious; this approach obviates many of the undesirable physiological side-effects of treatment with RAR antagonists.

Therapeutic combinations of RAR antagonists and RXR agonists and use

The present invention relates to a compound of the formula ##STR1## wherein X is --CONH-- or --NHCO--, or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof. The compounds of the present invention exhibit retinoid-like properties and are thus useful as antiinflammatory agents for chronic skin inflammatory diseases such as psoriasis and atopic dermatitis, as agents for the treatment of rheumatic diseases such as rheumatoid arthritis, as antitumor agents for the treatment of various tumors, and as agents for the treatment of non-malignant proliferative skin conditions.

Retinoid-like compounds

Certain novel substituted (5,6)-dihydroanthracenyl compounds of the general formula ##STR1## wherein A, n, p, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are as defined in the specification exhibit retinoid-like properties and are particularly useful in the prevention of post-surgical adhesions.

The present invention relates to a compound of formula ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in which

The present invention relates to a compound of formula I ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in which

Growing community of inventors

East Amherst, NY, United States of America

Peter R Reczek